Clustering-Based Method for Developing a Genomic Copy Number Alteration Signature for Predicting the Metastatic Potential of Prostate Cancer.
暂无分享,去创建一个
Jonathan Melamed | Harry Ostrer | H. Ostrer | Alex S Genshaft | J. Melamed | G. Bova | I. Holcomb | R. Schneider | A. Pearlman | Christopher L. Campbell | M. Ittman | Alexander Pearlman | Christopher Campbell | G Steven Bova | Eric Brooks | Alex Genshaft | Shahin Shajahan | Michael Ittman | Ilona Holcomb | Robert J Schneider | Ilona N. Holcomb | S. Shajahan | Eric L. Brooks | Shahin Shajahan | Robert J. Schneider
[1] M. Nagane,et al. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. , 2008, Neurosurgery.
[2] N. Sunaga,et al. l‐type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms , 2008, Cancer science.
[3] C. Creighton,et al. Genomic profiling of prostate cancers from African American men. , 2009, Neoplasia.
[4] Zhifu Sun,et al. A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer , 2006, PLoS medicine.
[5] Y. Kanai,et al. l‐Type amino acid transporter 1 inhibitors inhibit tumor cell growth , 2010, Cancer science.
[6] Jin Woo Kim,et al. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies , 2007, The Prostate.
[7] Jun Luo,et al. Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.
[8] Peter J. Park,et al. Comparative analysis of algorithms for identifying amplifications and deletions in array CGH data , 2005, Bioinform..
[9] Bert Vogelstein,et al. Genetic instability and darwinian selection in tumours , 1999 .
[10] Y. Kanai,et al. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. , 2008, Biological & pharmaceutical bulletin.
[11] D. Ross,et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A novel five-antibody immunohistochemical test for subclassification of lung carcinoma , 2010 .
[13] Jeffrey P. MacKeigan,et al. Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.
[14] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[15] M. Kattan,et al. Radical prostatectomy for carcinoma of the prostate , 2004, Modern Pathology.
[16] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[17] Terence P. Speed,et al. Genome analysis A genotype calling algorithm for affymetrix SNP arrays , 2005 .
[18] Hans Christian Pedersen,et al. Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy , 2010, Breast Cancer Research.
[19] J. Cheville,et al. Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer , 2009, Cancer investigation.
[20] E. Bergstralh,et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. , 2007, The Journal of urology.
[21] Gerhard Christofori,et al. Mechanisms of Motility in Metastasizing Cells , 2010, Molecular Cancer Research.
[22] J. Brooks,et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.
[23] 山内 宏一. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line , 2009 .
[24] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[25] Y. Kanai,et al. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. , 2009, Cancer letters.
[26] Y. Kanai,et al. L‐type amino‐acid transporter 1 as a novel biomarker for high‐grade malignancy in prostate cancer , 2009, Pathology international.
[27] S. Saydam,et al. Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer , 2009, Cancer science.
[28] M. Djamgoz,et al. Voltage‐gated K+ channel activity in human prostate cancer cell lines of markedly different metastatic potential: Distinguishing characteristics of PC‐3 and LNCaP cells , 2001, The Prostate.
[29] Joshua M. Korn,et al. Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs , 2008, Nature Genetics.
[30] Ying Yu,et al. Bcl-2 decreases voltage-gated K+ channel activity and enhances survival in vascular smooth muscle cells. , 2001, American journal of physiology. Cell physiology.
[31] Alexandre Mamedov,et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Y. Asmann,et al. A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy , 2008, PloS one.
[33] Y. Kanai,et al. Properties of L-Type Amino Acid Transporter 1 in Epidermal Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.
[34] N. Sunaga,et al. L‐type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non‐small cell lung cancer , 2009, Histopathology.
[35] H. Arakawa,et al. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. , 2010, Biochemical pharmacology.
[36] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.